ALBERTDAVDNSEAlbert David LimitedMediumNeutral
Announced Tue, 12 May · 19:31 IST

Albert David Limited has informed the Exchange about Re-appointment of M/s. S. Gupta & Co., Cost and Management Accountant, as the Cost Auditorsof the Company for the Financial Year 2026-27,

Ceo ResignedCeo Appointed ExternalKmp ResignedManagement Changes View source PDF

ALBERTDAVD · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-10.5%1-day move
₹790.00
prior close
₹730.00
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-1.9-1.9-2.3-2.1-10.5-8.6-10.1-9.2-10.4-10.6-8.8-8.3-11.2
Up moveDown movePending
AI summary

Albert David Limited held a Board Meeting on May 12, 2026, announcing several key developments. The company appointed Mr. Amit Mahla as CEO (effective immediately), following the resignation of Mr. Umesh Manohar Kunte from the Managing Director & CEO position effective December 18, 2025. The company reported audited FY2026 results showing a net loss of Rs 149.47 Lakhs, a significant decline from FY2025 profit of Rs 1,720.08 Lakhs, with Q4 standalone loss of Rs 2,143.44 Lakhs. Revenue from operations for FY2026 stood at Rs 33,359.81 Lakhs. The Board recommended a final dividend of Rs 5 per share (50% on Rs 10 face value) for FY2026, subject to shareholder approval at the 87th AGM scheduled for August 6, 2026. Both internal auditor (PricewaterhouseCoopers Services LLP) and cost auditor (S. Gupta & Co.) were re-appointed for FY2026-27. Statutory auditors L. B. Jha & Co. issued an unmodified audit opinion.

Likely market impact

The company faces financial headwinds with a net loss in FY2026, though the appointment of an experienced pharmaceutical executive as CEO may help reverse performance. The dividend recommendation provides some return to shareholders despite the challenging year.